Cutting-edge radiosurgery tech for brain tumours wins 2024 Falcons’ Fortunes

May 6, 2024 – At the sold-out Falcons’ Fortunes pitch competition hosted by FACIT, Dr. Hatim Fakir delivered the winning pitch as selected by the panel of judges for the $100,000 Ernsting Entrepreneurship Award. Developed at London Health Sciences Centre, Dr. Fakir’s RadioSphere is a patient-centred technology to revolutionize existing gamma knife radiotherapy procedures by providing the most precise tumour localization capabilities.

Read More from Cutting-edge radiosurgery tech for brain tumours wins 2024 Falcons’ Fortunes

Registration is now open for the 2024 Falcons’ Fortunes Pitch Finals – LIVE!

March 12, 2024 – You are invited to attend Falcons’ Fortunes, FACIT’s premier event to celebrate and grow the entrepreneurial spirit within the cancer research and innovation communities. Now in its 11th year, the Falcons’ Fortunes event features six Ontario rising stars pitching their breakthrough cancer innovation as they compete for the $100,000 Ernsting Entrepreneurship Award.

Read More from Registration is now open for the 2024 Falcons’ Fortunes Pitch Finals – LIVE!

Falcons’ Fortunes 2024 – Pitch Your Cancer Innovation

January 31, 2024 – Apply Now! FACIT invites entrepreneurs and scientists to pitch their Ontario-made cancer innovation to a panel of judges and in front of a live audience for a chance to win the $100,000 award. Falcons’ Fortunes is FACIT’s premier event to celebrate and grow the entrepreneurial spirit within the cancer research community to drive a culture of commercialization where Ontario-based cancer research discoveries becomes Ontario-made solutions to benefit patients worldwide.

Read More from Falcons’ Fortunes 2024 – Pitch Your Cancer Innovation

FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients battling cancer.

Read More from FACIT and T-CAIREM at the University of Toronto partner to commercialize medical AI

From Idea to Start up: FACIT President’s interview with Amanda Lang

May 1, 2023 – Watch FACIT President Dr. David O’Neill’s interview with Amanda Lang, host of Taking Stock on BNN Bloomberg. The episode, titled From Idea to Start up, originally aired on April 28, 2023. This was part of a special series about innovation in Canada and some of the challenges and opportunities.  FACIT was featured as a “success

Read More from From Idea to Start up: FACIT President’s interview with Amanda Lang

New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.

Read More from New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

FACIT generates $1.5 billion in follow-on investment

March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.

Read More from FACIT generates $1.5 billion in follow-on investment

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.

Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer